Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
| ▸ | HSD17B13 | Q7Z5P4 | 11/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30110935 | 0.82 | MAPT (0.43) | CNR1HSD17B13POLBALDH1A1KDM4E | |
| SCHEMBL14161796 | 0.81 | CNR1 (0.45) | CNR1HSD17B13ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL30110945 | 0.80 | POLB (0.44) | HSD17B13POLBALDH1A1KDM4EHSD17B10 | |
| SCHEMBL30111001 | 0.78 | HSD17B10 (0.49) | HSD17B13POLBALDH1A1KDM4EHSD17B10 | |
| SCHEMBL30111117 | 0.77 | ALDH1A1 (0.52) | HSD17B13POLBALDH1A1KDM4EHSD17B10 | |
| SCHEMBL30128842 | 0.76 | HSD17B13 (0.49) | HSD17B13POLBALDH1A1KDM4EHSD17B10 | |
| SCHEMBL30110965 | 0.76 | HSD17B13 (0.58) | CNR1HSD17B13KDM4E | |
| SCHEMBL30111220 | 0.74 | TRPA1 (0.49) | HSD17B13POLBKDM4E | |
| SCHEMBL30987296 | 0.74 | HSD17B13 (0.41) | CNR1HSD17B13ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL30459462 | 0.73 | PARP1 (0.47) | HSD17B13ALDH1A1KDM4EHSD17B10PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2024-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | PTPN1, PTPN5, PTPN2 | CNR1 3639/4885HSD17B13 2663/4885POLB 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.